NDUFB6

Across TCGA pan-cancer cohorts, NDUFB6 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of NDUFB6’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where NDUFB6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NDUFB6 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

LIHC, THCA, and BRCA are the cancer types where NDUFB6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NDUFB6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.711	<.001	8	view →
THCA	All	All	−0.334	<.001	8	view →
BRCA	All	III,IV	+0.319	.001	6	view →
KIRC	Male	All	−0.237	.002	6	view →
HNSC	Male	IV	+0.595	.001	3	view →
CHOL	All	II,III,IV	+0.594	.036	2	view →
STAD	All	IV	+1.003	.044	1	view →
READ	Female	All	−0.839	.012	1	view →
KICH	All	All	−0.453	.024	1	view →
KIRP	All	All	−0.301	.008	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

NDUFB6–LIHC

Open the LIHC breakdown →